Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...
5don MSN
Researchers found that the immunotherapy drug pembrolizumab significantly extends the cancer-free period for patients with ...
Professors Tom Powles and Peter Schmid recently delivered results from their phase three clinical trials during Sunday's ...
Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...
Aethlon's Hemopurifier® is a clinical stage immunotherapeutic device designed to combat cancer. Read the full article at Investorideas.com According to News-Medical.net, "Immunotherapy, which works ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...
Pfizer Canada ULC today announced that Health Canada has approved PADCEV ® (enfortumab vedotin) an antibody-drug conjugate (ADC) in combination with pembrolizumab, a PD-1 inhibitor, for the treatment ...
Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...
NIH clinical trial results expand treatment options for this disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback